Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment

Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment

Hepatocellular carcinoma (HCC) is the most common type of primary hepatic malignancy. HCC is one of the leading causes of cancer deaths worldwide. The oral multi-tyrosine kinase inhibitor Sorafenib is the standard first-line therapy in patients with advanced unresectable HCC. Despite the significant...

Full description

Bibliographic Details
Main Authors: Ritu Shrestha, Prashanth Prithviraj, Kim R. Bridle, Darrell H. G. Crawford, Aparna Jayachandran
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
hepatocellular carcinoma
EMT
immune checkpoint
sorafenib
PD-L1
Online Access:https://www.mdpi.com/2077-0383/10/9/1889

Similar Items

Similar Items